- Home
- SXTC vs PPCB Comparison
SXTC vs PPCB Comparison
Compare SXTC & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SXTC | PPCB |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | China | Australia |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SXTC | PPCB |
|---|---|---|
| Price | $2.10 | $0.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.2K | ★ 6.3M |
| Earning Date | 08-19-2019 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.10 |
| 52 Week High | $6.98 | $10.69 |
Technical Indicators
Market Signals| Indicator | SXTC | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 42.85 |
| Support Level | $1.88 | N/A |
| Resistance Level | $2.16 | $0.13 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 37.18 | 17.23 |
Price Performance
Historical ComparisonAbout SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.